Gemcitabine (G) followed by 2nd line Docetaxel (D) is feasible in advanced NSCLC: Results from a randomized phase II study

Saved in:

Bibliographic Details
Published in	Lung cancer (Amsterdam, Netherlands) Vol. 29; no. 1; pp. 11 - 12
Main Authors	Manegold, C, Pitz, L, Koschel, G, Schott, K, Waletzko, E, Hruska, D, Dornoff, W, Gosse, H, Gatzemeier, U
Format	Journal Article
Language	English
Published	01.09.2000
Online Access	Get full text

Loading…

More Information
ISSN:	0169-5002
DOI:	10.1016/S0169-5002(00)80032-X